Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brimocholâ„¢ PF (combination of carbachol and brimonidine tartrate) is a preservative-free topical ophthalmic solution which is used to lower pressure in the eyes, it is being investigated for the treatment of presbyopia.
Product Name : Brimochol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2023
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brimocholâ„¢ PF (combination of carbachol and brimonidine tartrate) is a preservative-free topical ophthalmic solution which is used to lower pressure in the eyes, it is being investigated for the treatment of presbyopia.
Product Name : Brimochol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2023
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Zhaoke Ophthalmology
Deal Size : $130.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, ZKO will be responsible for clinical development and regulatory approval for BRIMOCHOL PF and Carbachol PF in the specified territories, and subsequently the commercialization activities for the products.
Product Name : Brimochol
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
November 05, 2022
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Zhaoke Ophthalmology
Deal Size : $130.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting
Details : Non-clinical work with BRIMOCHOL PF demonstrating additive effects of brimonidine on the pharmacokinetics and pharmacodynamics of carbachol proved predictive of our clinical results showing contribution of elements in our Phase 2 study.
Product Name : Brimochol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from Phase 2 trial, demonstrate that BRIMOCHOL, a fixed-dose combination of carbachol (a cholinergic miotic agent) and brimonidine tartrate (an alpha-2 agonist), is a safe and effective once-daily eye drop to correct the loss of near vision assoc...
Product Name : Brimochol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : LSP
Deal Size : $20.0 million
Deal Type : Financing
Visus Secures $20 Million in Additional Financing Led by New Investor LSP
Details : Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline.
Product Name : Brimochol
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 08, 2021
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : LSP
Deal Size : $20.0 million
Deal Type : Financing
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $36.0 million
Deal Type : Series A Financing
Details : Proceeds from the Series A financing will be used to advance the clinical development program for the company’s lead asset, BRIMOCHOL™, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated wit...
Product Name : BRIMOCHOL
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 03, 2021
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $36.0 million
Deal Type : Series A Financing
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Visus Therapeutics Initiates Phase 2 Clinical Trial of BRIMOCHOL for the Treatment of Presbyopia
Details : The Phase 2 clinical trial is a double-masked, randomized crossover study designed to evaluate the safety and efficacy of two proprietary formulations of BRIMOCHOL topical ophthalmic solution in patients with emmetropic phakic and pseudophakic presbyopia...
Product Name : Brimochol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2021
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable